China Shenghuo sees 19% rise in Q1 sales
China Shenghuo’s net income was $85,701, or $0.01 per diluted share, compared to net income of $13,825, or $0.00 per diluted share, for the comparable period last year.
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.